A biopharmaceutical company
Prescription Drug User Fee Act reauthorization.
Diabetes drugs issues.
H.R. 5651, Food and Drug Administration Reform Act of 2012.
S. 2516, Food and Drug Administration Safety and Innnovation Act. S. 3187, Food and Drug Administration Safety and Innovation Act.
S. 2292, Patients' FDA Act
"Track and trace" issues. Diabetes research issues. Diabetes issues.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation).
Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation). Medicare coverage and reimbursement issues.
Diabetes issues.
H. Con. Res 112, Establishing the budget for the US Government for FY 2013.
Pub. L. 111-148, Patient Protection and Affordable Care Act (implementation). Pub. L. 111-152, Health Care and Education Reconciliation Act of 2010 (implementation).
PHA - Pharmacy MED - Medical/Disease Research/Clinical Labs HCR - Health Issues MMM - Medicare/Medicaid
135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE 135 - Food & Drug Administration (FDA) 2 - HOUSE OF REPRESENTATIVES 1 - SENATE
PODESTA GROUP, INC.
1001 G Street, NW, Suite 1000 West, Washington, DC, 20001, US
ANTHONY PODESTA SHARON COHEN OSCAR RAMIREZ THOMAS B SPARKMAN JAIME R HARRISON (Policy Adviser, Rep. James Clyburn) CLAUDIA JAMES ISRAEL S KLEIN (Comm. Director, Sen. Charles Schumer) SHARON COHEN THOMAS B SPARKMAN SHARON COHEN THOMAS B SPARKMAN SHARON COHEN THOMAS B SPARKMAN
Policy Adviser, Rep. James Clyburn Comm. Director, Sen. Charles Schumer